Pacesetter, Inc.

St Jude Medical, Atrial Fibrillation Division, Inc

St. Jude Medical Ab

Other

St. Jude Medical, Cardiology Division, Inc.

Tc1 LLC

Pacestter, Inc.

Kyungmoo Ryu

Stuart Rosenberg

Allen J Keel

Gene A Bornzin

Xiaoyi Min

Michael Xiaoxuan Yang

Jong Gill

Wenbo Hou

Yelena Nabutovsky

Kjell Noren

Steve Koh

Nima Badie

Taraneh Ghaffari Farazi

Fujian Qu

Luke C McSpadden

Thao Thu Nguyen

Keith Victorine

Gabriel A Mouchawar

Edward Karst

Wenwen Li

Tomas Svensson

Avi Fischer

Hoda Razavi

Euljoon Park

Xing Pei

Jan O Mangual-Soto

Yun Qiao

Thao T Ngo

Sven-Erik Hedberg

Annapurna Karicherla

Chunlan Jiang

Kjell Norén

Aditya Goil

Caroline D Jordan

David Muller

Rupinder Bharmi

Zoltan Somogyi

Valtino X Afonso

Benjamin T Persson

Fady Dawoud

Cyrille Casset

Heidi Hellman

Weiqun Yang

Michael J Coyle

Shubha Asopa

John W Poore

John R Helland

Thomas Flavian Strange

Brian Jeffrey Wenzel

Richard P Williamson

Michael E Benser

Cecilia Qin Xi

Martin Cholette

Louis-Philippe Richer

Anders Bjorling

Riddhi Shah

Joseph Beauvais

Thanh Tieu

Jatin Surendra Relan

Lalit Venkatesan

Ryan Rooke

Rohan More

Alexander R Bornzin

Hanbiao Wang

William Hsu

Stephanie C Sun

Leyla Sabet

Nalin S Perera

Kyle J Nix

Michael Hardage

Prakrit Shrestha

Enzo Silipo

Philip B Adamson

Catherine Tan

Gene Bomzin

System for arrhythmia detection and confirmation includes implantable medical device (IMD) having a sensing circuit for sensing cardiac activity (CA) for one or more cardiac cycles and generating one or more CA signals. An implantable pressure sensor (IPS) includes IPS sensing circuit for sensing pressure during the one or more cardiac cycles and generating one or more pressure signals. IMD and IPS include communications circuits for communicating with each other and/or an external device. One or both of IMD or IPS includes memory for storing program instructions and processor(s) for analyzing one of the CA or pressure signals, for one or more cardiac cycles, to detect a candidate arrhythmia. In response to detecting candidate arrhythmia, the processor(s) obtain another one of CA or pressure signals for cardiac cycles corresponding to the one or more cardiac cycles, and confirm or deny candidate arrhythmia based on the other one of the signals.

System and method for inter-device arrhythmia detection and confirmation

A biostimulator and a biostimulator system for septal pacing, is described. The biostimulator includes a burrowing nose to allow the biostimulator to embed within a target tissue. The embedded biostimulator has a reduced exposed length within a heart chamber, and is less likely to interfere with adjacent heart structures. Embodiments include burrowing ridges on a nose or a housing of the biostimulator to affix the embedded biostimulator to the target tissue. Other embodiments are also described and claimed.

Biostimulator having burrowing nose

A system is provided that includes a first electrode configured to be located within a septal wall, and a second electrode configured to be located outside of the septal wall. The system also includes an impedance circuit configured to measure impedance along an impedance monitoring (IM) vector between the first and second electrodes. One or more processors are also provided that are configured to obtain impedance data indicative of an impedance along the IM vector with the first electrode located at different depths within the septal wall, the impedance data including a set of data values associated with different depths of the first electrode within the septal wall. The one or more processors are also configured to determine when the first electrode is located at a target depth within the septal wall based on the impedance data.

Method and system for implanting a septal wall electrode

Described herein are methods for use with an implantable system including at least an atrial leadless pacemaker (aLP). Also described herein are specific implementations of an aLP, as well as implantable systems including an aLP. In certain embodiments, the aLP senses a signal from which cardiac activity associated with a ventricular chamber can be detected by the aLP itself based on feature(s) of the sensed signal. The aLP monitors the sensed signal for an intrinsic or paced ventricular activation within a ventricular event monitor window. In response to the aLP detecting an intrinsic or paced ventricular activation itself from the sensed signal within the ventricular event monitor window, the aLP resets an atrial escape interval timer that is used by the aLP to time delivery of an atrial pacing pulse if an intrinsic atrial activation is not detected within an atrial escape interval.

Ventricular far-field sensing to guide atrial leadless pacemaker and beyond

A subcutaneous implantable medical device and method (SIMD) provided. A pulse generator (PG) is configured to be positioned subcutaneously within a lateral region of a chest of a patient. The PG has a housing that includes a PG electrode. The PG has an electronics module. An elongated lead is electrically coupled to the pulse generator. The elongated lead includes a first electrode that is configured to be positioned along a first parasternal region proximate a sternum of the patient and a second electrode that is configured to be positioned at an anterior region of the patient. The first and second electrodes are coupled to be electrically common with one another. The electronics module is configured to provide electrical shocks for antiarrhythmic therapy along at least one shocking vector between the PG electrode and the first and second electrodes.

Implantation medical device with multiple parasternal-anterior electrodes

A system and method are provided for managing atrial-ventricular (AV) delay adjustments. An AV interval is measured that corresponds to an interval between an atrial paced (Ap) event or an atrial sensed (As) event and a sensed ventricular (Vs) event. A candidate AV delay is set based on the AV interval and a bundle branch adjustment (BBA) value. A QRS characteristic of interest (COI) is measured while utilizing the candidate AV delay in connection with delivering a pacing therapy. The BBA value is adjusted and the candidate AV delay is reset based on the BBA value as adjusted. A collection of QRS COIs and corresponding candidate AV delays are obtained and one of the candidate AV delays is selected as a BBA AV delay. The pacing therapy is managed, based on the BBA AV delay.

Systems and methods for managing atrial-ventricular delay adjustments

System and methods are provided for determining a stimulation threshold for closed loop spinal cord stimulation (SCS). The system and methods provide a lead coupled to an implantable pulse generator (IPG). The system and methods deliver SCS pulses from the IPG to the lead electrodes in accordance with an SCS therapy and determine an evoked compound action potential (ECAP) amplitude based on an ECAP waveform resulting from the SCS therapy. The system and methods increase the SCS therapy by increasing at least one of an amplitude, a duration, and number of the SCS pulses associated with the SCS therapy. The system and methods also include iteratively repeat the delivering, determining and increasing operations until the ECAP amplitude exhibits a downward trend divergence. The system and methods define a stimulation threshold based on the ECAP amplitude at the trend divergence.

System and method for determining a stimulation threshold for closed loop spinal cord stimulation

A system for verifying a candidate pathologic episode of a patient is provided. The system includes an accelerometer configured to be implanted in the patient, the accelerometer configured to obtain accelerometer data along at least one axis. The system also includes a memory configured to store program instructions and one or more processors. When executing the program instructions, the one or more processors are configured to obtain a biological signal and identify a candidate pathologic episode based on the biological signal, analyze the accelerometer data to identify a physical action experienced by the patient, and verify the candidate pathologic episode based on the physical action.

System for verifying a pathologic episode using an accelerometer

The present disclosure provides systems and methods for applying anti-tachycardia pacing (ATP) using subcutaneous implantable cardioverter-defibrillators (SICDs). An SICD implantable in a subject includes a case including a controller, and at least one conductive lead extending from the case. The at least one conductive lead includes a plurality of coil electrodes, wherein the SICD is configured, via the controller, to apply anti-tachycardia pacing (ATP) to the subject using the at least one conductive lead.

Systems and methods for applying anti-tachycardia pacing using subcutaneous implantable cardioverter-defibrillators

Subcutaneous implantation medical device with multiple parasternal-anterior electrodes

Described herein are methods, devices, and systems that use electrogram (EGM) or electrocardiogram (ECG) data for sleep apnea detection. An apparatus and method detect potential apnea events (an apnea or hypopnea event) using a signal indicative of cardiac electrical activity of a patient's heart, such as an EGM or ECG. Variations in one or more morphological or temporal features of the signal over several cardiac cycles are determined and used to detect a potential apnea event in a measurement period. Checks can then be made for a number of factors which could result in a false detection of an apnea event and if such factors are not present, an apnea event is recorded. Described herein are also methods, devices, and systems for classifying a patient as being asleep or awake, which can be used to selectively enable and disable sleep apnea detection monitoring, as well as in other manners.

Methods, systems, and devices for detecting sleep and apnea events

A method and device for dynamic device based AV delay adjustment are provided. The method provides electrodes that are configured to be located proximate to an atrial (A) site and a right ventricular (RV) site. The method utilizes one or more processors, in an implantable medical device (IMD), for detecting an atrial paced (Ap) event or atrial sensed (As) event. The method determines a measured AV interval corresponding to an interval between the Ap event or the As event and a ventricular sensed event and calculates a percentage-based (PB) offset based on the measured AV interval. The method automatically dynamically adjusting an AV delay, utilized by the IMD, based on the measured AV interval and the PB offset and manages a pacing therapy, utilized by the IMD, based on the AV delay after the adjusting operation.

Method and system utilizing a percentage-based atrio-ventricular delay adjustment

Computer implemented methods and systems for monitoring cardiac activity (CA) signals, for a series of beats, over first and second sensing channels having different first and second detection thresholds, respectively. The methods and systems also include analyzing the CA signals over the first and second sensing channels utilizing the first and second detection thresholds, respectively, during an event prediction window to detect a presence of sensed events. The methods and systems also include determining amplitudes of the sensed events detected. The methods and systems also include calculating at least one of an amplitude distribution or amplitude trend for the sensed events detected over the first and second channels and adjusting at least one of the first or second detection thresholds based on the at least one of the amplitude distribution or amplitude trend.

Method and system for adaptive-sensing of electrical cardiac signals

Growing community of inventors

Palmdale, CA, United States of America

Kyungmoo Ryu